Novo Nordisk

NOVO-B.CO NVO
Fwd P/E11.0
EV/EBITDA7.4
P/B5.4
P/S3.4
Div Yield5.1%
ROE60.7%
Revenue
309BDKK
2016: 111780.0 2017: 111696.0 2018: 111831.0 2019: 122021.0 2020: 126946.0 2021: 140800.0 2022: 176954.0 2023: 232261.0 2024: 290403.0 2025: 309064.0 2026E: 285437.0 2027E: 300022.7
Gross Profit
250BDKK
2016: 94597.0 2017: 94064.0 2018: 94214.0 2019: 101933.0 2020: 106014.0 2021: 117142.0 2022: 148506.0 2023: 196496.0 2024: 245881.0 2025: 250276.0
EBIT
128BDKK
2016: 48432.0 2017: 48967.0 2018: 47248.0 2019: 52483.0 2020: 54126.0 2021: 58644.0 2022: 74809.0 2023: 102574.0 2024: 128339.0 2025: 127658.0
Net Income
102BDKK
2016: 37925.0 2017: 38130.0 2018: 38628.0 2019: 38951.0 2020: 42138.0 2021: 47757.0 2022: 55525.0 2023: 83683.0 2024: 100988.0 2025: 102434.0
EPS
23.03DKK
2016: 15.0 2017: 15.4 2018: 15.9 2019: 16.4 2020: 18.0 2021: 20.7 2022: 24.4 2023: 18.6 2024: 22.6 2025: 23.0 2026E: 20.9 2027E: 21.4
Op. Cash Flow
119BDKK
2016: 48314.0 2017: 41168.0 2018: 44616.0 2019: 46782.0 2020: 51951.0 2021: 55000.0 2022: 78887.0 2023: 108908.0 2024: 120968.0 2025: 119102.0
Gross Margin
81.0%
2016: 84.6 2017: 84.2 2018: 84.2 2019: 83.5 2020: 83.5 2021: 83.2 2022: 83.9 2023: 84.6 2024: 84.7 2025: 81.0
Op. Margin
41.3%
2016: 43.3 2017: 43.8 2018: 42.2 2019: 43.0 2020: 42.6 2021: 41.7 2022: 42.3 2023: 44.2 2024: 44.2 2025: 41.3
LT Debt
119BDKK
2018: 0.0 2019: 3009.0 2020: 2897.0 2021: 0.0 2022: 24318.0 2023: 20528.0 2024: 89674.0 2025: 118941.0
ROIC
35.9%
2016: 144.6 2017: 123.9 2018: 105.9 2019: 100.0 2020: 84.9 2021: 68.0 2022: 65.7 2023: 75.8 2024: 48.0 2025: 35.9
Dividends
52BDKK
2016: 23830.0 2017: 18844.0 2018: 19048.0 2019: 19409.0 2020: 20121.0 2021: 21517.0 2022: 25303.0 2023: 31767.0 2024: 44140.0 2025: 51763.0
NOVO-B.CO · Weekly

News

Why Novo Nordisk Can't Catch Up Eli Lilly Despite Wegovy Pill Success
CNBC · 2026-04-07
CNBC explains how Novo's weight loss pill faces competition from Eli Lilly's oral GLP-1.
Novo Nordisk launches higher-dose Wegovy in the United States
Reuters · 2026-04-07
Novo Nordisk launches higher-dose Wegovy in the US market.

Comments